Completed PHASE1 INTERVENTIONAL 1-arm NCT02182609

99mTc-rhAnnexin V-128: a First In Man Study in Healthy Volunteers

A Phase I Study of Safety, Tolerance, Pharmacokinetics and Nuclear Medicine Imaging of 99mTc-rhAnnexin V-128 Administered Intravenously in Healthy Adult Volunteers

Sponsor: Advanced Accelerator Applications

Conditions Healthy Adult Volunteers

Interventions Kit for the Preparation of 99mTc-rhAnnexin V-128

Updated 6 times since 2017 Last updated: Nov 20, 2019 Started: Apr 30, 2013 Primary completion: Oct 31, 2014 Completion: Aug 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy Adult Volunteers, this trial is completed. The trial is conducted by Advanced Accelerator Applications and has accumulated 6 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Dec 2019 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Dec 2019 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Apr 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Advanced Accelerator Applications
Atreus Pharmaceuticals Corporation

Data source: Advanced Accelerator Applications

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ottawa, Canada